布地奈德福莫特罗粉联合噻托溴铵粉治疗慢性阻塞性肺疾病的临床效果

Clinical Effect of Budesonide Formoterol Powder Combined with Tiotropium Bromide Powder in the Treatment of Chronic Obstructive Pulmonary Disease

目的探讨慢性阻塞性肺疾病(慢阻肺)稳定期患者采用布地奈德福莫特罗粉联合噻托溴铵粉治疗的效果。方法选取钢城区人民医院2022年10月—2023年10月收治的84例慢阻肺稳定期患者为研究对象,随机将其分为对照组和研究组,每组42例。对照组采用噻托溴铵粉治疗,研究组采用布地奈德福莫特罗粉联合噻托溴铵粉治疗。比较两组患者的炎症因子水平、血气指标、肺功能指标、治疗有效率及不良反应发生率。结果治疗30 d后,研究组的白细胞介素-6、C反应蛋白、降钙素原水平分别为(15.24±2.34)pg/mL、(10.23±2.08)mg/L、(4.12±0.31)ng/mL,均低于对照组的(18.65±3.48)pg/mL、(14.56±2.37)mg/L、(5.78±0.32)ng/mL,组间差异有统计学意义(P<0.05)。治疗30 d后,研究组的血氧分压为(82.56±4.38)mmHg,高于对照组的(74.35±5.12)mmHg,血二氧化碳分压为(50.45±3.12)mmHg,均低于对照组的(58.23±2.68)mmHg,组间差异有统计学意义(P<0.05)。治疗30 d后,研究组的用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC分别为(2.78±0.54)L、(1.96±0.47)L、(80.45±4.32)%,均大于对照组的(1.85±0.83)L、(1.52±0.54)mL、(74.16±4.28)%,组间差异有统计学意义(P<0.05)。研究组的治疗总有效率为97.62%,高于对照组的80.95%,差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论布地奈德福莫特罗粉联合噻托溴铵粉治疗慢阻肺的效果理想,能明显降低患者的炎症反应,改善其血气指标和肺功能,且不良反应少,有较高的推广应用价值。

Objective To investigate the effect of budesonide formoterol powder combined with tiotropium bromide powder on patients with chronic obstructive pulmonary disease(COPD)in stable stage.Methods A total of 84 patients with COPD in stable stage admitted to the Gangcheng District People's Hospital from October 2022 to October 2023 were selected as the research objects and were randomly divided into a control group and a research group,with 42 cases in each group.The control group was treated with tiotropium bromide powder,and the research group was treated with budesonide formoterol powder and tiotropium bromide powder.The levels of inflammatory factors,blood gas indexes,lung function indexes,treatment effectiveness and incidence of adverse reactions were compared between the two groups.Results After 30 days of treatment,the levels of interleukin-6,C-reactive protein and procalcitonin in the research group were(15.24±2.34)pg/mL,(10.23±2.08)mg/L and(4.12±0.31)ng/mL,respectively,which were lower than(18.65±3.48)pg/mL,(14.56±2.37)mg/L,(5.78±0.32)ng/mL in control group,and the differences between the groups were statistically significant(P<0.05).After 30 days of treatment,the blood oxygen partial pressure of the research group was(82.56±4.38)mmHg,higher than(74.35±5.12)mmHg of the control group,and the blood carbon dioxide partial pressure was(50.45±3.12)mmHg,lower than(58.23±2.68)mmHg of the control group,the differences between the groups were statistically significant(P<0.05).After 30 days of treatment,the forced vital capacity(FVC),forced expiratory volume(FEV_(1))and FEV_(1)/FVC of the research group were(2.78±0.54)L,(1.96±0.47)L and(80.45±4.32)%,respectively,which were greater than(1.85±0.83)L,(1.52±0.54)mL and(74.16±4.28)%in the control group,and the differences between the groups were statistically significant(P<0.05).The total effective rate of the research group was 97.62%,which was higher than 80.95%of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Budesonide formoterol powder combined with tiotropium bromide powder has an ideal effect in the treatment of COPD,which can significantly reduce the inflammatory response of patients,improve the blood gas indexes and lung function,and have fewer adverse reactions,so it has high application value.